News | July 07, 2023
Dabur India expects 10%+ consolidated growth in Q1 FY24
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
This acquisition will significantly strengthen Croda’s Beauty Actives portfolio and increases its exposure to targeted prestige segments
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
PEEK brings a new quality to dental care for patients
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Subscribe To Our Newsletter & Stay Updated
